Psychedelic profiles: MDMA
Last year MAPS completed its Phase IIIa trials with MDMA in the treatment of PTSD. The subsequent data release grabbed headlines internationally, with MDMA expected to be the first classic psychedelic medicine approved for clinical use in the 21st century.
MDMA was first synthesised in 1912 by Dr Anton Köllisch at Merck, and patented by the company in 1914. However, its therapeutic utility lay undiscovered until research by acclaimed tryptamine chemist Alexander Shulgin half a century later. Shulgin introduced the compound to his wife, a psychotherapist, for use in couples therapy.
MDMA is an empathogen, a psychoactive chemical that elicits feelings of empathy, similar in structure to both mescaline and methamphetamine. In response to a rise in recreational use in nightclubs, the DEA declared an emergency ban on MDMA in 1985, despite its medical potential.Read More